246 related articles for article (PubMed ID: 9224607)
41. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
42. Maxizyme technology.
Iyo M; Kawasaki H; Taira K
Methods Mol Biol; 2004; 252():257-65. PubMed ID: 15017055
[TBL] [Abstract][Full Text] [Related]
43. Aberrant BCR-ABL transcript with intronic insertion in a patient with philadelphia chromosome-positive chronic myeloid leukemia: implications for disease progression.
Shiratsuchi M; Muta K; Minami R; Motomura S; Suehiro Y; Abe Y; Shiokawa S; Umemura T; Fukui T; Nishimura J; Nawata H
Leuk Lymphoma; 2001 Apr; 41(3-4):411-5. PubMed ID: 11378554
[TBL] [Abstract][Full Text] [Related]
44. Working at the cutting edge: the creation of allosteric ribozymes.
Warashina M; Kuwabara T; Taira K
Structure; 2000 Nov; 8(11):R207-12. PubMed ID: 11080644
[TBL] [Abstract][Full Text] [Related]
45. "Hairpin" and "hammerhead" ribozymes directed towards the mumps virus nucleocapsid RNA: specific cleavage of a small synthetic RNA substrate and full-length mRNA.
Albuquerque-Silva J; De Vos MJ; Bollen A; Houard S
Virus Genes; 1996; 13(3):211-9. PubMed ID: 9035365
[TBL] [Abstract][Full Text] [Related]
46. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
47. Modified binary hammerhead ribozymes with high catalytic activity.
Vorobjeva M; Gusseva E; Repkova M; Kovalev N; Zenkova M; Venyaminova A; Vlassov V
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):1105-9. PubMed ID: 16248101
[TBL] [Abstract][Full Text] [Related]
48. The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia.
Inokuchi K; Nomura T
Leuk Lymphoma; 1993 May; 10(1-2):9-15. PubMed ID: 8374529
[TBL] [Abstract][Full Text] [Related]
49. Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?
Kronenwett R; Haas R
Recent Results Cancer Res; 1998; 144():127-38. PubMed ID: 9304714
[No Abstract] [Full Text] [Related]
50. Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity.
Shimayama T; Sawata S; Komiyama M; Takagi Y; Tanaka Y; Wada A; Sugimoto N; Rossi JJ; Nishikawa F; Nishikawa S
Nucleic Acids Symp Ser; 1992; (27):17-8. PubMed ID: 1283905
[TBL] [Abstract][Full Text] [Related]
51. Detection of bcr-abl fusion mRNA in chronic myelogenous leukemia by reverse transcription polymerase chain reaction using nested primers.
Furukawa Y; Ju SL; Cho HL; Tatsumi N
Osaka City Med J; 1993 Jun; 39(1):35-45. PubMed ID: 7694218
[TBL] [Abstract][Full Text] [Related]
52. Detection of bcr/c-abl mRNA in chronic myelogenous leukemia by polymerase chain reaction to identify chromosome translocation.
Lin CP; Chen PM; Yen JS; Wang RL; Lee LS; Chen PH; Chang JG
J Formos Med Assoc; 1992 Mar; 91(3):247-51. PubMed ID: 1354683
[TBL] [Abstract][Full Text] [Related]
53. Allosterically controllable maxizymes for molecular gene therapy.
Iyo M; Kawasaki H; Taira K
Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
[TBL] [Abstract][Full Text] [Related]
54. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Mundhada S; Luthra R; Cano P
BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
[TBL] [Abstract][Full Text] [Related]
55. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
56. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
Giles RV; Spiller DG; Green JA; Clark RE; Tidd DM
Blood; 1995 Jul; 86(2):744-54. PubMed ID: 7606003
[TBL] [Abstract][Full Text] [Related]
57. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
58. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
[TBL] [Abstract][Full Text] [Related]
59. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
Mol Cell; 1998 Nov; 2(5):617-27. PubMed ID: 9844634
[TBL] [Abstract][Full Text] [Related]
60. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
